Table 3.

Association between Two-fold Higher Baseline ApoC-III and eGFR Decline

Analysis	eGFR decline, ml/min/1.73 m2 (95 % CI)	P-Value
Model 1	−1.62 (−1.93, −1.31)	<0.001
Model 2	−0.46 (−0.80, −0.13)	0.007
Model 3	−0.38 (−0.72, −0.05)	0.026
Model 4	−0.22 (−0.60, 0.16)	0.257

Data represent eGFR change per year for every two-fold increase of log-transformed plasma apoC-III concentration, analyzed as a continuous variable. Linear regression through mixed effects modeling was performed in incremental models with the following co-variates

Model 1: Age, gender, race, baseline SCr

Model 2: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering medications, smoking, alcohol use, hemoglobin A1c

Model 3: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering medications, smoking, alcohol use, hemoglobin A1c, urinary ACR

Model 4: Age, gender, race, baseline SCr, BMI, hypertension, lipid-lowering medications, smoking, alcohol use, hemoglobin A1c, urinary ACR, triglyceride levels

*Definition of hypertension includes the use of anti-hypertensive medications

SCr serum creatinine, ACR albumin to creatinine ratio